Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

April 10, 2026

Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium

MONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced details on RESET-PSVT, a planned Phase 4, multicenter, prospective, observational registry intended to generate real-world evidence on the use of CARDAMYST™ (etripamil) nasal spray in adults with paroxysmal supraventricular tachycardia (PSVT)**.** "Registry of Etripamil (CARDAMYST™) Studies Evaluating Treatment in Paroxysmal Supraventricular Tachycardia (RESET-PSVT): Study Design," was presented in a poster session at the Preventive Cardiovascular Nurses Association (PCNA) 2026 Cardiovascular Nursing Symposium in Scottsdale, Arizona. The study will be led by the Duke Clinical Research Institute (DCRI).

CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) in December 2025 and is now commercially available in the United States.

RESET-PSVT is expected to enroll an estimated 450 adult patients across approximately 20 electrophysiology and cardiology sites, with enrollment beginning by the end of 2026. The registry is designed to evaluate patients who have been prescribed CARDAMYST as well as patients prescribed or given other therapies, with enrolled patients and their healthcare providers completing patient- and provider-outcome surveys, respectively.

"RESET-PSVT will be important in further expanding the evidence base for CARDAMYST beyond our controlled clinical trials and into real-world clinical practice," said David Bharucha, M.D., PhD, Chief Medical Officer of Milestone Pharmaceuticals. "This registry is designed to help us better understand how CARDAMYST is being used in adults with PSVT in routine care, while also capturing patient-reported outcomes that can provide meaningful insight into how patients are living with this condition. In addition to evaluating treatment patterns, we believe the study has the potential to deepen our understanding of quality of life, episode burden and healthcare utilization over time. This is the first registry of its kind in the PSVT space, and we expect it to inform healthcare providers, support future scientific dialogue and further characterize the value of CARDAMYST in the acute management of PSVT."

The study's primary endpoint is to characterize patterns of use of CARDAMYST in PSVT management, including frequency of PSVT episodes, frequency of use of CARDAMYST, number of doses administered per episode and triggers for use. Secondary endpoints include comparisons between CARDAMYST and non-CARDAMYST users across patient-reported quality of life, healthcare utilization and episode characteristics. Exploratory analyses are expected to evaluate prescribing and use patterns across patient subgroups, along with qualitative analysis of participant experience.

"We believe this registry is important because it is designed to capture meaningful patient-reported outcomes in a contemporary PSVT population," said Sean D. Pokorney, M.D., MBA, RESET-PSVT Lead Investigator and Assistant Professor of Medicine at Duke University School of Medicine and the Duke Clinical Research Institute (DCRI). "In addition to informing how CARDAMYST is being used in practice, these data may provide valuable insight into quality of life, healthcare utilization and the broader patient experience over time."

RESET-PSVT is intended to generate prospective evidence to inform the real-world use of recently approved CARDAMYST and demonstrate its potential impact on the acute management of PSVT. Results are expected to be shared at scientific conferences and in peer-reviewed publications in the future.

In addition, an expert theater "Discover the First and Only FDA-Approved Nasal Spray to Treat PSVT in Adults," sponsored by Milestone, will take place April 11 during the PCNA symposium.

Product Theater: **Discover the First and Only FDA-Approved Nasal Spray to Treat PSVT in Adults**

Presenter: Eleanor C. Vierra, NP, ACNP-C, Cardiovascular Acute Care Nurse Practitioner
Day/Time: Saturday, April 11, 8:00am MT

About CARDAMYST
CARDAMYST™ (etripamil) nasal spray is approved by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is a novel calcium channel blocker nasal spray designed as a self-administered rapid response therapy for patients, thereby bypassing the need for immediate medical oversight. The product is intended to provide health care providers with a new treatment option to enable on-demand care and patient self-management. This portable treatment may provide patients with active management and a greater sense of control over their condition. CARDAMYST is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT. Currently, etripamil is in Phase 2 development for treatment of PSVT in pediatric patients and Phase 3 development for control of acute atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults. For more information, please visit CARDAMYST.com.

Indication
CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

IMPORTANT SAFETY INFORMATION FOR CARDAMYST (etripamil)

What is CARDAMYST?
CARDAMYST is a prescription medicine used to help restore normal sinus heart rhythm in adults who have symptoms of sudden episodes of fast heartbeat called paroxysmal supraventricular tachycardia (PSVT).

It is not known if CARDAMYST is safe and effective in children.

Do not use CARDAMYST if you:

- are allergic to CARDAMYST or any of its ingredients. See the Patient Information for a complete list of ingredients in CARDAMYST.
- have limitations in activities due to heart failure (moderate to severe heart failure).
- have Wolff-Parkinson-White (WPW) syndrome, Lown-Ganong-Levine syndrome, or an abnormal heart rhythm pattern called pre-excitation (delta wave) on an electrocardiogram (ECG).
- have sick sinus syndrome without a permanent pacemaker.
- have second degree or higher atrioventricular (AV) block.

Before using CARDAMYST, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of fainting.
- have low blood pressure.
- are pregnant or plan to become pregnant. It is not known if CARDAMYST will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if CARDAMYST passes into your breast milk. You should stop breastfeeding for 12 hours after treatment with CARDAMYST. During this time, pump and throw away your breast milk. Talk to your healthcare provider about the best way to feed your baby after using CARDAMYST.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of CARDAMYST?

CARDAMYST may cause serious side effects, including:

- **Fainting due to CARDAMYST effects on blood pressure, heart rate, and electrical activity of the heart.** CARDAMYST may cause dizziness and fainting, especially in people with a history of fainting and certain heart problems, or people with a history of fainting during an episode of PSVT. Use CARDAMYST while sitting in a safe area where you will not fall if you become dizzy or lightheaded. Lie down if you feel dizzy or lightheaded after using CARDAMYST. If fainting occurs after using CARDAMYST, caregivers should place you on your back and seek medical help.

The most common side effects of CARDAMYST include:

• nasal discomfort • nasal congestion • runny nose	• throat irritation • nosebleed

These are not all of the possible side effects for CARDAMYST. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see the full Prescribing Information https://milestonepharma.com/etripamilprescribinginformation.pdf for CARDAMYST.

About the Duke Clinical Research Institute
The DCRI, part of the Duke University School of Medicine, is the largest academic clinical research organization in the world. The DCRI's mission is to develop, share, and implement knowledge that improves global health through innovative clinical research. The institute conducts multinational clinical trials, manages major national patient registries, and performs landmark outcomes research. The DCRI is a pioneer in cardiovascular and pediatric clinical research and conducts groundbreaking clinical research across multiple other therapeutic areas, including infectious disease, neuroscience, respiratory medicine, and nephrology. To learn more, visit dcri.org.

About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone's lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "continue," "could," "demonstrate," "designed," "develop," "estimate," "expect," "may," "pending," "plan," "potential," "progress," "will", "intend" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify

forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding: Milestone's expectations in regard to the efficacy of etripamil and its safe self-administration by patients outside the clinical setting; Milestone's research, development and regulatory plans for etripamil; and other statements not related to historical facts. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether Milestone's future interactions with the EMA will have satisfactory outcomes; whether and when, if at all, Milestone's MMA for etripamil will be approved by the EMA; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of Milestone's clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs, Russian hostilities in Ukraine and ongoing disputes in the Middle East and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission (SEC), including in its annual report on Form 10-K for the year ended December 31, 2025 under the caption "Risk Factors," as such discussions may be updated from time to time by subsequent filings Milestone may make with the SEC. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com

Media Relations
Rebecca Novak, rnovak@milestonepharma.com

Source: Milestone Pharmaceuticals Inc.